Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis

Background:
The aim of this study was to investigate the protective effect of interleukin-6 (IL-6) receptor antagonist tocilizumab (TCZ) on rheumatoid arthritis (RA) and its related mechanism.

Material/Methods:
Thirty RA patients receiving long-term methotrexate therapy at moderate and severe active stages were selected and treated with TCZ 8 mg/kg/time iv gtt intravenously guttae every 4 weeks. Peripheral blood was extracted before and 24 weeks after TCZ treatment. Peripheral blood mononuclear cells (PBMC) were collected by density gradient centrifugation. Flow cytometry was used to detect the ratio of CD4 naïve T cells and CD4 memory T cells, Th17 cells, and Treg cells in PBMC. DAS28 score, CRP, RF, and CCP levels in patients were evaluated.

Results:
Compared with before treatment, IL-6 receptor antagonist TCZ significantly improved patients’ condition, including DAS28 score, CRP, RF, and CCP levels (P<0.01). Furthermore, TCZ obviously upregulated CD4 naïve T cells proportion and decreased CD4 memory T cells ratio (P<0.01). TCZ also markedly reduced the proportion of Th17 cells and increased the proportion of Treg cells (P<0.01).

Conclusions:
TCZ can treat RA patients through regulating the ratio of CD4 naïve T cells, CD4 memory T cells, Th17 cells, and Treg cells in PBMC.

MeSH Keywords:
Antibodies, Bispecific • Antibodies, Monoclonal • Proton-Motive Force • Rheumatoid Factor

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/896355
Rheumatoid arthritis (RA) is a type of autoimmune disease characterized by chronic synovitis and bone erosion [1–3]. The pathogenesis of RA is still unclear. A variety of natural immune and acquired immune cells are involved in the RA process [4]. CD4 T cells abnormality has been confirmed to be the core cause of RA pathogenicity in human and mouse studies [5–7]. CD4 T cells are divided into naïve CD4 T cells and memory CD4 T cells. It was reported that the imbalance between naïve CD4 T cells and memory CD4 T cells plays a role in autoimmune disease [8]. Th17 cells and Treg cells were also found to have critical effects in RA. The proportion of Th17 cells is increased [9] and the proportion of Treg cells is decreased [10] in RA.

At first, researchers thought that reducing the number of lymphocytes and other immune cells or weakening their function could alleviate RA. This was confirmed by CD4 monoclonal antibody preliminary clinical trials, which also showed that it can slightly improve the condition of RA patients [11]. In addition, using CD20 monoclonal antibody to remove B cells can also improve RA patient condition [12].

Tocilizumab (TCZ), a humanized interleukin (IL)-6 receptor monoclonal antibody, is a recently developed biological agent that can effectively relieve RA disease [13]. An original study showed that IL-6 was a cytokine required for B cell differentiation [14]; therefore, TCZ can obviously change the proportion of B cells in peripheral blood in treating RA. However, IL-6 also plays an important role in T cell differentiation (Th1, Th2, and Th17) and Treg cell formation [15]. A recent study showed that TCZ can treat RA through mediating the Th1/Treg balance [15], but the mechanism by which TCZ works in RA treatment is not fully understood because of issues involving sample size, research cycle, and cell subset detection. Therefore, the present study used TCZ to treat RA patients and detected the ratio of CD4 naïve T cells and CD4 memory T cells, Th17 cells, and Treg cells in peripheral blood mononuclear cells (PBMC).

**Material and Methods**

**Clinical subjects**

Thirty RA patients receiving long-term methotrexate therapy at moderate and severe active stages were enrolled in this research at Tianjin People’s Hospital of Nankai University. All the subjects were females, with a mean age at 35.53±11.47 (25–48) years old. The BMI range was 20–25, and the RA course was 0.5–3 years. Methotrexate therapy was used for more than 3 months.

This study was pre-approved by the Ethics Committee of Tianjin People’s Hospital of Nankai University. Written informed consent was obtained from all subjects.

**Treatment method**

Ten patients were treated by TCZ 8 mg/kg/time iv gtt intravenously guttae every 4 weeks.

**PBMC extraction**

Peripheral blood was extracted immediately before and at 24 weeks after TCZ treatment [16]. PBMC were collected by density gradient centrifugation. Peripheral blood was diluted by RPMI-1640 (Hyclone) at 1:1. Ten ml diluted peripheral blood was added to a 15-ml tube containing 5 ml lymphocyte separation medium (GE Healthcare) and centrifuged at 800 g for 18 min. After removing the white membrane layer, the liquid was moved to another 15-ml tube containing 10 ml serum-free RPMI-1640 medium and centrifuged at 600 g for 15 min. The cell sediment was resuspended in 10 ml serum-free RPMI-1640 medium and centrifuged at 400 g for 8 min. The collected cells were counted after trypan blue staining and used for the following experiment.

**Peripheral blood CD4 naïve T cells and CD4 memory T cells ratio assay**

PBMC was washed twice with PBS containing 5% BSA and centrifuged at 400 g for 8 min. After removing the supernatant, the cells were incubated in APC-CD4, PE-CD45 RA, and APC-CD45 RO at 4°C for 30 min in the dark. After washing twice with PBS containing 5% BSA and centrifuging at 400 g for 8 min, the cells were resuspended in 100 μl PBS for detection.

**Th17 cell proportion detection**

PBMC were pretreated by cell stimulus (Biolegend) for 6 h. The cells were washed twice with PBS containing 5% BSA and centrifuged at 400 g for 8 min. After removing the supernatant, the cells were incubated in APC-CD4, PE-CD45 RA, and APC-CD45 RO at 4°C for 30 min in the dark. After washing twice with PBS containing 5% BSA and centrifuging at 400 g for 8 min, the cells were resuspended in 100 μl PBS for detection.

**Treg cells proportion detection**

After incubation in APC-CD4, the PBMC, separated as described above, were then incubated in APC-Foxp3 antibody
after removing the supernatant and were resuspended in 100 μl PBS for detection.

**Statistical analysis**

SPSS16.0 software was used for data analysis. The t test was used for mean value comparison. P<0.05 was considered as statistically significant.

**Results**

**IL-6 receptor antagonist TCZ effect on patient condition**

As shown in Figure 1, DAS28 score, CRP, RF, and CCP levels before treatment were 4.84±1.23, 42.80±22.09 mg/L, 319.98±172.63 U/ml, and 738.25±437.41 U/ml, respectively. After TCZ treatment, DAS28 score, CRP, RF, and CCP levels were 2.61±0.63, 1.63±0.94 mg/L, 154.40±100.64 U/ml, and 135.85±67.85 U/ml, respectively. Compared with before treatment, TCZ treatment significantly decreased DAS28 score, CRP, RF, and CCP levels (P<0.01).

**TCZ impact on CD4 naïve T cells and CD4 memory T cells ratio in peripheral blood**

As shown in Figure 2, the proportion of CD4+CD45RA+ T cells and CD4+CD45RO+ T cells were 28.64±8.86% and 68.93±14.64% before treatment, respectively whereas they were 41.35±11.74% and 41.85±10.35% after TCZ therapy, respectively. TCZ obviously upregulated CD4+CD45RA+ T cells proportion and decreased CD4+CD45RO+ T cells ratio (P<0.01).

**TCZ impact on Th17 cells proportion in peripheral blood**

Th17 cells proportion was 1.53±0.46% before treatment, and it declined significantly to 0.46±0.16% after TCZ treatment (P<0.01) (Figure 3).

**TCZ impact on Treg cells ratio in peripheral blood**

As shown Figure 4, TCZ treatment obviously increased Treg cells ratio in peripheral blood, from 1.84±0.63% to 5.53±1.62% (P<0.01).

**Discussion**

RA is a chronic systemic inflammatory disease mainly involving bone, synovial joints, and ligaments. Severe RA patients may be affected in all organs [1–3]. In addition, it also can produce effects in cardiovascular, lung, and blood systems [17]. The incidence of RA in adults is about 1–2% [18]. Multiple types of innate immune and acquired immune cells are involved in the RA process [4]. CD4 T cell abnormality was confirmed to be the main cause of RA in human and mouse studies [5–7]. In addition, Th17 cells and Treg cells also play an important role in RA [9,10]. Because RA mainly involves the joints, it has high morbidity and seriously affects ability to work and perform activities of daily living. Furthermore, RA can shorten life span and imposes a huge burden on patients and society. Thus, there is an urgent need to find effective drug treatments for RA in clinical application.

Currently, commonly used biological agents for RA in clinical settings include tumor necrosis factor (TNF)-α inhibitor (etanercept and infliximab) and recombinant humanized IL-6 receptor monoclonal antibody TCZ (ACTEMRA) [19,20]. TNF-α...
inhibitor was explored early-on and its mechanism is relatively clear. Research showed that Treg cells’ immunosuppression function in RA patients’ synovia was significantly reduced by Foxp3 phosphorylation [20]. TNF-α inhibitor treatment obviously changed Foxp3 phosphorylation and recovered Treg cells’ immunosuppression function [20]. Shen et al. [21] revealed that TNF-α inhibitor significantly reduced Th17 cells ratio in peripheral blood and serum IL-17 level. TCZ was recently developed, and the mechanism by which it works in treating RA is not fully understood.
CRP may increase during infection, injury, or inflammation, and its elevation in RA usually indicates active stage, while its decrease indicates stable stage. RF is the antibody of degenerated IgG induced by infection factors, and its elevation is closely associated with bone destruction. CCP shows good sensitivity and specificity to RA, especially in bone destruction. For CRP, RF, and CCP characteristics in RA, their levels can effectively reflect patient condition. This study showed that TCZ significantly improved patient condition by decreasing DAS28 score, CRP, RF, and CCP levels by more than half ($P<0.01$). Our results are consistent with previous reports of TCZ remarkably improving RA patients at moderate and severe active stages [22].

We further analyzed the mechanism of TCZ in treating RA. It was reported that compared with healthy people, RA patients presented obviously lower CD4 naïve T cells proportion and elevated CD4 memory T cells ratio, suggesting that an imbalance between CD4 naïve T cells and CD4 memory T cells is closely associated with autoimmune disease [23]. Our results confirmed that, compared with before treatment, TCZ significantly increased CD4 naïve T cells percentage and decreased CD4 memory T cells ratio ($P<0.01$), indicating that TCZ can improve RA condition through regulating the balance between CD4 naïve T cells and CD4 memory T cells. In addition, an imbalance in the proportion Th17 cells and Tregs cells in peripheral blood was related to RA, presenting as Th17 cells ratio upregulation and Tregs cells ratio reduction [9,24]. Our results revealed that TCZ obviously decreased Th17 cells proportion and Treg cells percentage in peripheral blood ($P<0.01$).

**Conclusions**

TCZ can be used to treat RA patients through regulating the ratio of CD4 naïve T cells, CD4 memory T cells, Th17 cells, and Treg cells in peripheral blood.

**Conflicts of interest**

The authors declare they have no competing financial or commercial interests in this manuscript.

**References:**

1. Sennikov SV, Alshevskaya AA, Shkaruba NS et al: Expression of TNFalpha membrane-bound receptors in the peripheral blood mononuclear cells (PMBC) in rheumatoid arthritis patients. Cytokine, 2015; 73: 288–94
2. Joaquim AF, Ghizoni E, Tedeschi H et al: Radiological evaluation of cervical spine involvement in rheumatoid arthritis. Neurosurg Focus, 2015; 38: E4
3. Chieng LO, Madhavan K, Vanni S: Pooled data analysis on anterior versus posterior approach for rheumatoid arthritis at the craniovertebral junction. Neurosurg Focus, 2015; 38: E18
4. McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med, 2011; 365: 2205–19
5. Okada Y, Terao C, Ikari K et al: Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet, 2012; 44: 511–16

6. Scally SW, Petersen J, Law SC et al: A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med, 2013; 210: 2569–82

7. Kremer JM, Westhoven R, Leon M et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med, 2003; 349: 1907–15

8. Gessl A, Wilfling A, Agis H, Steiner G et al: Activated naive CD4+ peripheral blood T cells in autoimmune thyroid disease. Thyroid, 1995; 5: 117–25

9. Venkatesha SH, Dudics S, Weingartner E et al: Altered Th17/Treg balance and dysregulated IL-1beta response influence susceptibility/resistance to experimental autoimmune arthritis. Int J Immunopathol Pharmacol, 2015; 28: 318–28

10. Byng-Maddick R, Ehrenstein MR: The impact of biological therapy on regulatory T cells in rheumatoid arthritis. Rheumatology (Oxford), 2015; 54: 768–75

11. Choy EH, Panayi GS, Emery P et al: Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford), 2002; 41: 1142–48

12. Tak PP, Rigby WF, Rubbert-Roth A et al, Investigators I: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGe trial. Ann Rheum Dis, 2011; 70: 39–46

13. Nam JL, Ramiro S, Gaujoux-Viala C et al: Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis, 2014; 73: 516–28

14. Kishimoto T: Factors affecting B-cell growth and differentiation. Annu Rev Immunol, 1985; 3: 133–57

15. Kikuchi J, Hashizume M, Kaneko Y et al: Peripheral blood CD4+CD25+CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther, 2015; 17: 10

16. Nakashima Y, Kondo M, Miyahara H, Iwamoto Y: Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab. Drug Des Devel Ther, 2014; 8: 913–19

17. Wasserman BR, Moskovich R, Razi AE: Rheumatoid arthritis of the cervical spine – clinical considerations. Bull NYU Hosp Jt Dis, 2011; 69: 136–48

18. Gillick JL, Walmwright J, Das K: Rheumatoid arthritis and the cervical spine: A review on the role of surgery. Int J Rheumatol, 2015; 2015: 252456

19. Nakajima T, Kawabata D, Nakabo S et al: Successful treatment with tocilizumab in a case of intralymphatic histiocytosis associated with rheumatoid arthritis. Intern Med, 2014; 53: 2255–58

20. Nie H, Zheng Y, Li R et al: Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med, 2013; 19: 322–28

21. Shen H, Xia L, Lu J, Xiao W: Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Investig Med, 2010; 58: 905–8

22. Wang G, Mu R, Xu H: Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations. Int J Gen Med, 2015; 8: 187–94

23. Walter GJ, Fleskens V, Frederiksen KS et al: Phenotypic, functional and gene expression profiling of peripheral CD45RA+ and CD45RO+ CD4+CD25+CD127 regulatory T cells in rheumatoid arthritis. Arthritis Rheumatol, 2015 [Epub ahead of print]

24. Lee J, Baek S, Lee J et al: Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. Int Immunopharmacol, 2015; 26: 103–11